Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo

International Journal of Radiation Oncology Biology Physics

Volumn 88, Issue 5, 2014, Pages 1180-1187

  Agoni, Lorenzo ^a   Basu, Indranil ^a   Gupta, Seema ^a,b   Alfieri, Alan ^a   Gambino, Angela ^c   Goldberg, Gary L ^a   Reddy, E Premkumar ^d   Guha, Chandan ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Biophysics Research Institute of America   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELLS; IRRADIATION; PATIENT TREATMENT; TUMORS;

CELL CYCLE ANALYSIS; CERVICAL CANCER CELLS; CLONOGENIC SURVIVAL ASSAYS; CONCURRENT CHEMORADIATION; FLUORESCENCE-ACTIVATED CELL SORTERS; METHODS AND MATERIALS; MODIFICATION FACTORS; RADIO-SENSITIZATION;

PLATINUM COMPOUNDS;

CISPLATIN; DNA; GAMMA H2AX PROTEIN; PROTEIN; RIGOSERTIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL SURVIVAL; CHEMORADIOTHERAPY; CLONOGENIC ASSAY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROPIDIUM IODIDE ASSAY; PROTEIN EXPRESSION; RADIOSENSITIZATION; SURVIVAL RATE; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL SEPARATION; CELL SURVIVAL; CHEMORADIOTHERAPY; CISPLATIN; DNA DAMAGE; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FLOW CYTOMETRY; GLYCINE; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; MITOSIS; NEOPLASM TRANSPLANTATION; RADIATION-SENSITIZING AGENTS; SULFONES; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84897059196     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.12.051     Document Type: Article

References (17)

1. K. Gumireddy, M.V. Reddy, and S.C. Cosenza et al. On01910, a non-ATP-competitive small molecule inhibitor of plk1, is a potent anticancer agent Cancer Cell 7 2005 275 286
2. M.V. Reddy, P. Venkatapuram, and M.R. Mallireddigari et al. Discovery of a clinical stage multi-kinase inhibitor sodium (e)-2-{2-methoxy-5-[(2',4',6'- trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): Synthesis, structure-activity relationship, and biological activity J Med Chem 54 2011 6254 6276
3. M. Roschewski, M. Farooqui, and G. Aue et al. Phase I study of ON 01910.Na (rigosertib), a multikinase PI3K inhibitor in relapsed/refractory b-cell malignancies Leukemia 27 2013 1920 1923
4. M. Seetharam, A.C. Fan, and M. Tran et al. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na Leuk Res 36 2012 98 103
5. A. Prasad, I.W. Park, and H. Allen et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells Oncogene 28 2009 1518 1528
6. A.C. Fan, J.J. O'Rourke, and D.R. Praharaj et al. Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer Expert Opin Investig Drugs 22 2013 1495 1509
7. C.M. Chapman, X. Sun, and M. Roschewski et al. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3k/AKT inhibition and induction of oxidative stress Clin Cancer Res 18 2012 1979 1991
8. J.A. Engelman, J. Luo, and L.C. Cantley The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat Rev Genet 7 2006 606 619
9. D.W. Bowles, and A. Jimeno New phosphatidylinositol 3-kinase inhibitors for cancer Exp Opin Invest Drugs 20 2011 507 518
10. D.R. Taft, R. Dave, and A.M. Gillum et al. ON 01910.Na Drugs Future 36 2011 433 440
11. E. Vrdoljak, and W. Hamm Current state-of-the-art of concomitant chemoradiation in cervical carcinomas Eur J Gynaecol Oncol 24 2003 475 479
12. J. Green, J. Kirwan, and J. Tierney et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix Cochrane Database Syst Rev 2005 CD002225
13. F.A. Stewart, A. Luts, and Y. Oussoren et al. Renal damage in mice after treatment with cisplatin and x-rays: Comparison of fractionated and single-dose studies NCI Monogr 1988 23 27
14. N.A. Franken, H.M. Rodermond, and J. Stap et al. Clonogenic assay of cells in vitro Nat Protoc 1 2006 2315 2319
15. C.L. Rieder, and H. Maiato Stuck in division or passing through: What happens when cells cannot satisfy the spindle assembly checkpoint Dev Cell 7 2004 637 651
16. G.D. Wilson, S.M. Bentzen, and P.M. Harari Biologic basis for combining drugs with radiation Semin Radiat Oncol 16 2006 2 9
17. S. Ahmad Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes Chem Biodivers 7 2010 543 566